Jaguar Health Inc (JAGX) News

all information was available in the poster presentation in San Antonio, where I attended :) take care bears

onset and sustained efficacy

a larger portion of patients with breast cancer receiving crofolemer were responders for all 3 months
p value long term = 0.0123
that means 💲

patients with breast cancer showed significant improvement with crofolemer over placebo
p value = 0.0245

In a drug trial, a "good" p-value is generally considered to be less than 0.05; this means that there is less than a 5% chance that the observed results occurred by random chance, indicating a statistically significant difference between the drug and the control group.

Will this pos ever make some money for the share holders...so many pr's making no difference

This stock has been a bane to me.

No news about the partnership at the conference or after the conference....

Up 30% on 2m volume, any idea what's cookin?

This stock really got hammered the past few years.

Suspect its on a 'life support' device
hidden in a locked room.

With a couple of folks still around
with a mission of trying to figure out
how to keep the plug from being pulled.

Disclaimer: did get out with some 'gains' cause
I sold out before the news hit. And only reason
for dropping 'in' was cause I was curious to see what
was being said (and I haven't deleted the board cause
I am curious to see if they will be able to take another
run at it)

Is this thing dead now?

The market conditions are rough right now pending political events.

JAGX new 52=week low

That's why I chose to exit my position for now

Fuc k November...and F uck Conte

I think data was as expected. Look, cancer patients on TARGETED therapies have a 95% chance of getting CID. Breast and Lung cancer patients in ONTARGET received TARGETED therapies. So, if it worked on 75% of the patients. Which is the group were 95% of the patients get CID, the trial is succesfull... simple.

HOWEVER, I exited my position for the following reason: In my opinion there was not shared any detailed information, because the principal investigator wants to take the data to SABCS (breast cancer symposium), like they did with the phase 2 trial.

I've seen it with other stocks that the principal investigators prefere this. And they decide where data is presented. So in my opinion we can wait for the full data till december 9th (SABCS)

So, unless the POC data for SBS and MVIS shows up, or a a new partnership... it will be a long wait, and shorts will take it down again. That's why I chose to exit, but I will be back in november

Scam POS over 20 years endless printing shares and r/s.

WOW I was close to jump on this a few days ago...I ned a break trading these loser pennies

What your plan Shadow? You are/were a big supporter, do you think the data is good? Any chances of recovery or it’s just another ?

This CEO needs to be investigated. The RS was BS, the "imminent" publishing of data??? These have totally screwed the shareholder, and she damn well knew exactly what was happening, or this thing would have been sub penny.

For sure not a good stock at all unless around 5 cents then I can play with it. Free ATM for the CEO all they do offering dumping and RS

I was owning shares. 75% down.

Data was GOOD, as I predicted. Can't blame my own DD

Can blame management. Wtf was that for a shit show. No complete data, horrible press release. Horrible managed

I really don't think Shadow ever owned any shares. He was just here to spout lies about the results and try to get the last drop of money out of the remaining unsuspected shareholders....koddos to you shadow. Great job. This will be back to 5 cents again in no time... Another offering , another reverse split maybe they'll change their name to TIGX... Same criminals , same outcome. CEO waited till now because she's leaving for her European trip and Africa trip tomorrow. She just wanted to get the frig out of Dodge before the death threats started.

Me too. They try and BS everyone with the “we have to do this to stay in the nasdaq”. That kills the shareholder especially when like you said, it will be at a nickel again soon. Glad I got out as soon as I heard anything about a reverse split and how good it was going to be for the company and shareholders. Not even good for the company because no one has faith or trust in the controlling interests anymore.

lol idiot

right lol .... big redddddd

right lol .....

mr brains how is your account????
i knowwww biggggg redddddd

look at the pps i told you idiots

JAGX new 52 week low

So happy I got out before RS this junk one so dead years ago but I will buy some when it drops to 5 cents which it’s coming soon

Mayday!!!!

Yes, after the next reverse split! LOL

Yes, after the next reverse split! LOL

I got out while I was ahead pre-split, and she is Definitely Not My CEO!!! LOL You must have me confused with someone else???

With that said I was really hoping for the ones who went through the reverse split here could have gotten paid and not had their cakes taken by this CEO Twice!

Do you still see 10$ coming??

I have no words. Only bad, horrible ones, that are unspeakable.

They will continue to dilute and next year will probably do another massive reverse split. I was really hoping for the current shareholders that this study would have come out positive and that this could have seen some very nice gains.

ShadowDiviner is speechless.....We waited 5 years for this ....omfg... So CEO JUST OUTRIGHT LIED ? Cmon back and defend your great CEO.....what an absolute azzfuc

Holy Crap? What happened here???

Yea, I guess I am confused. After reading through the results, it sounds like the subgroups did see market improvements. So, to me it sounds like positive news. However it did not meet all their expectations.

What was everyone else's take away?

this was not supposed to cure cancer or shrink tumors - they made it sound like a failure

Picking up some shares down here

Subgroup patients comprised of 75% of the trial - Lung and breast meaningful and relevant

Did NOT meet its end point.. wow..

https://archive.fast-edgar.com/20240723/ATB2M62C8Z22SZZ222ZG2ZZZI5GSH2S2D26G/tm2419925d1_ex99-1.htm

SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced the results from its initial analysis of the pivotal Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy. Crofelemer is an FDA-approved prescription drug for the symptomatic relief of diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy. The initial results from the OnTarget study show that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types in the trial.

“While the results of the OnTarget study did not achieve significance for all tumor types receiving various targeted therapies, I am pleased that the subgroup analyses show that crofelemer provides clinically meaningful improvement in the prespecified subgroups of breast and respiratory tumor patients. Clinical meaningfulness of these results is based on the information provided by solid tumor patients from a survey that informed us about the appropriate clinical study design and clinical endpoints, that are important to the patients in this prophylactic trial. We will continue to evaluate important OnTarget findings, with further analyses,” said Pablo Okhuysen, MD, Professor of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, who is the Principal Investigator of the OnTarget clinical trial. “It is important to note that the prespecified secondary outcomes for this study were based on outcomes that were considered to be meaningful by patients experiencing diarrhea due to targeted therapy.”

KEY TAKE-A-WAYS FROM ONTARGET TRIAL

· Unprecedented OnTarget trial included patients with 10 different tumor types and 24 different targeted agents, with and without multiple standard cytotoxic chemotherapies.
· Study did not meet prespecified analysis of primary endpoint for all tumor types.
· Analysis did reveal clinically relevant signals for patients in the prespecified subgroups of breast and respiratory cancers, including lung cancer, who received targeted therapies. These subgroups of patients comprised over 75% of the patients in the trial.
· Breast and lung cancers are two of the three most common cancers, with patients often remaining on targeted therapy over prolonged periods.
· A growing and urgent unmet medical need exists for novel non-opioid chronic agents to treat CTD.
· Results indicate positive signals improved over the initial 12-week phase of study; data for additional 12-week extension phase yet to be analyzed.
· Company expects to engage with FDA after full review of data.

It should be MANDATORY that companies post the PR on their website the

instant its released.

IF I could see the PR, this could be a potential 'deal'

Wonder whats driving the sell off??

Shorts are ready to take it down

Stock is going to 1.00

People got scared maybe?